Replies to post #210964 on Biotech Values

[DewDiligence]

RDUS selling $345M convertible debt on unspecified terms:

https://globenewswire.com/news-release/2017/08/07/1081277/0/en/Radius-Health-Announces-Proposed-Public-Offering-of-300-Million-of-Convertible-Senior-Notes-due-2024.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

RDUS -39% on failure to show non-inferiority of its new transdermal delivery system of osteoporosis drug to regular administration of the same drug:

https://www.globenewswire.com/news-release/2021/12/08/2348411/31149/en/Radius-Announces-Results-from-the-wearABLe-Trial-Evaluating-Abaloparatide-Transdermal-System-in-Postmenopausal-Women-with-Osteoporosis.html